Asthma diagnosis and treatmentMild to moderate asthma affects lung growth in children and adolescents
Section snippets
CAMP trial
Detailed descriptions of the design and methods of the CAMP have been published previously.27, 29 CAMP was a prospective, randomized, double-masked, multicenter trial composed of 1041 children age 5 to 12 years with mild to moderate asthma demonstrated during a screening period by the presence of 8 or more days with asthma symptoms or a peak flow less than 80% personal best (mean days without symptoms or low peak flow, 9.7 ± 7.4 in 28-day period) and a positive methacholine challenge (mean PC20
Lung function growth
Both sexes in CAMP and children without asthma follow similar growth curves for FEV1 and FVC. Attained FEV1 and FVC for girls are approximately 1.0 to 1.5 L, respectively, less than boys. Average FEV1 and FVC in boys continues to increase through age 18 years, but begins to plateau around age 17 years, whereas girls' lung growth begins to slow around age 14 years.
FEV1 in CAMP and the children without asthma for both sexes were similar at ages 5 to 7 years, with the FEV1 for children without
Discussion
This comparison of longitudinal lung growth in CAMP and subjects without asthma has allowed us to demonstrate that mild to moderate persistent asthma can result in abnormalities in FEV1, FVC, and FEV1/FVC. In the CAMP participants, these abnormalities increase in magnitude from ages 5 to 18 years in both boys and girls. Of the lung functions measured, reductions in FEV1/FVC are the most prominent effect of asthma, resulting from the combined effect of an overall reduction in FEV1 growth and an
References (41)
Pathogenic mechanisms and natural histories of the disorders
Med Clin North Am
(1990)- et al.
Irreversible lung function deficits in young adults with a history of childhood asthma
J Allergy Clin Immunol
(2005) - et al.
Extrinsic and intrinsic asthma from childhood to adult age: a 10-yr follow-up
Respir Med
(1995) - et al.
Follow-up of asthma from childhood to adulthood: influence of potential childhood risk factors on the outcome of pulmonary function and bronchial responsiveness in adulthood
J Allergy Clin Immunol
(1994) - et al.
Occult pulmonary abnormalities in asymptomatic asthmatic children
Chest
(1977) - et al.
The role of allergy and nonspecific airway hyperresponsiveness in the pathogenesis of chronic obstructive pulmonary disease
Am Rev Respir Dis
(1989) - et al.
The relationship between respiratory illness in childhood and chronic airflow obstruction in adulthood
Am Rev Respir Dis
(1983) - et al.
Relationships between duration of asthma and asthma severity among children in the Childhood Asthma Management Program (CAMP)
J Allergy Clin Immunol
(1999) - et al.
Relationship between increased airway responsiveness and asthma severity in the Childhood Asthma Management Program
Am J Respir Crit Care Med
(2000) - et al.
Pubertal growth curves of ventilatory function: relationship with childhood respiratory symptoms
Am Rev Respir Dis
(1993)
Classifying asthma severity in children: mismatch between symptoms, medication use and lung function
Am J Respir Crit Care Med
Effects of asthma on pulmonary function in children: a longitudinal population-based study
Am Rev Respir Dis
The natural history of childhood asthma to adult life
BMJ
Sex-specific effects of asthma on pulmonary function in children
Am J Respir Crit Care Med
Sex differences in factors associated with childhood- and adolescent-onset wheeze
Am J Respir Crit
Longitudinal study of pulmonary function development in childhood, adolescence, and early adulthood
Am Rev Respir Dis
Lung function in young adults who had asthma in childhood
Am Rev Respir Dis
Childhood asthma and adult lung function
Am Rev Respir Dis
Childhood asthma and lung function in mid-adult life
Pediatr Pulmonol
Gender- and race-specific effects of asthma and wheeze on level and growth of lung function in children in sex U.S. cities
Am J Respir Crit Care Med
Cited by (0)
The Childhood Asthma Management Program is supported by contracts NO1-HR-16044, 16045, 16046, 16047, 16048, 16049, 16050, 16051, and 16052 with the National Heart, Lung, and Blood Institute and General Clinical Research Center grants M01RR00051, M01RR0099718-24, M01RR02719-14, and RR00036 from the National Center for Research Resources.
Disclosure of potential conflict of interest: R. C. Strunk, S. T. Weiss, J. Tonascia, and K. P. Yates have received grant support from the National Heart, Lung, and Blood Institute. R. C. Strunk and S. T. Weiss have also received grant support from the National Center for Research Resources. R. S. Zeiger has consultant arrangements with AstraZeneca, Genentech, GlaxoSmithKline, Merck, Novartis, and Sanofi-Aventis and has received grant support from AstraZeneca, Genentech, GlaxoSmithKline, Merck, Novartis, Sanofi-Aventis, and the National Heart, Lung, and Blood Institute. S. J. Szefler has consultant arrangements with AstraZeneca, Genentech, GlaxoSmithKline, Merck, and Aventis, and has received grant support from the National Institutes of Health, the National Heart, Lung, and Blood Institute, NIAID, and Ross Pharmaceuticals.
- ∗
The members of the research group are listed in this article's Online Repository at www.jacionline.org.